Persoporc™

Product information

Porcine Reproductive and Respiratory Syndrome, or PRRS, continues to be one of the most economically important diseases in global swine production. It impacts reproductive performance, piglet viability, respiratory health, and overall herd productivity. The constant evolution and genetic diversity of PRRSV make long-term control particularly challenging for veterinarians and producers, especially under field conditions with multiple circulating strains.

Persoporc™ is a next-generation modified live virus (MLV) vaccine designed to provide enhanced protection against PRRSV2. It is based on an innovative chimeric virus design combining two PRRSV2 lineage 5 strains, LMY and BP2017-2, and incorporates Synthetic Attenuated Virus Engineering (SAVE) to optimize safety, immunogenicity and genetic stability.

By combining chimeric technology, codon pair deoptimization (CPD) and CpG optimization, Persoporc™ is designed to slow viral replication while preserving key protective viral structures. This approach helps stimulate both humoral and cell-mediated immune responses, supporting broad cross-protection against diverse PRRSV2 strains, including relevant heterologous lineages.

How does Persoporc™ chimera technology support PRRSV2 cross-protection?

Chimera technology is widely recognized for its role in improving PRRSV vaccine cross-protection. Persoporc™ uses the LMY strain for non-structural proteins, ORF1a and ORF1b, and the BP2017-2 strain for structural proteins, ORFs 2–7. This combination supports a strong immune response and broad protection against PRRSV2 strains, helping address previous challenges related to vaccine efficacy, safety and cross-protection.

How does SAVE technology and Codon Pair Deoptimization (CPD) improve vaccine and stability?

SAVE technology targets the NSP1 protein, which plays an important role in immune evasion and viral replication. Through codon pair deoptimization (CPD), nucleotide sequences are modified without changing the encoded protein structure. This slows NSP1 production and reduces viral replication, while maintaining a stable and attenuated vaccine strain with a very low risk of reversion to virulence.

This attenuation strategy is designed to support a strong safety profile, with reduced viremia, extremely low viral shedding and a very low risk of recombination with circulating field strains.

How does CpG optimization enhance the immune response?

To further enhance immunity, Persoporc™ increases cytosine (C) before guanine (G) sequences, known as CpG sites, in the viral genome. CpG optimization helps stimulate stronger cell-mediated immunity (CMI) while reducing immune evasion. This ensures a robust and effective immune response, even with slower viral replication rates.

By stimulating both humoral and cell-mediated immunity, Persoporc™ helps support improved herd health, reduced clinical symptoms and better productive performance in modern swine production systems.